DOCTORS have urged action to tackle “unjust” inequalities faced by BAME groups as new research found discrepancies in health-related outcomes between minorities and white Britons.
Those of Bangladeshi, Pakistani, Arab, and Gypsy or Irish Traveller backgrounds were considered to have a 20-year age difference in their health status, compared to those from equivalent white backgrounds, recent research published in The Lancet Public Health showed.
Ethnic groups were more likely to have underlying health conditions, poor experiences of primary care, insufficient support from local services and high area-level social deprivation, researchers found.
Responses were collected from patients registered at GP practices across England from July 2014 to April 2017, prior to the pandemic.
Researchers looked at how ethnicity was associated with five self-reported health issues – mobility, self-care, activity such as working or housework, pain or discomfort, and anxiety or depression. They then gave each patient a “health-related quality of life” for each ethnic group, ranging from perfect health (1) to poorest health (-5.94). The study found that on average, each of the five main ethnic groups scored poorer than white Britons, to the extent that it was as if patients from these groups were 20 years older than their counterparts.
The British Medical Association (BMA) council chair, Dr Chaand Nagpaul, said the study highlighted the “enormous and unjust” health inequalities faced by minority ethnic groups in the UK. He warned the issues have prevailed for “far too long”.
The ongoing pandemic has further exacerbated the social, ethnic and economic divides within Britain, Dr Nagpaul added. Since the coronavirus outbreak last year, studies have consistently shown ethnic groups have been disproportionately impacted by the virus.
“Indeed, it would be short sighted not to see that health inequalities are partly to blame for the high Covid-19 death rates in this country,” Dr Nagpaul told Eastern Eye. “The dearth of public health provision reduces the life chances of already socially disadvantaged and clinically vulnerable groups – this must be urgently addressed.”
Dr Habib Naqvi is the director of the NHS Race and Health Observatory, an independent group working to tackle ethnic and racial inequalities in healthcare for patients, communities and the NHS workforce. Noting the findings, Dr Naqvi said the observatory was committed to closing the gaps in healthcare access and outcomes between ethnic groups.
“We know structural health inequalities blight the lives of many people from ethnic minority groups in disparaging and, often, life-limiting ways,” he told Eastern Eye. “It is therefore crucially important that we address the persistent and troubling problem of ethnic inequalities in relation to health.”
Dr Kailash Chand, the honorary vice-president for the BMA, told Eastern Eye any systematic investigation of any inequities in access to care has been “hampered by the failure of NHS institutions to collect ethnicity data on patients both at hospital and primary care level”.
Dr Kailash Chand called for action, rather than more reviews and reports on inequalities
“There is some evidence that the NHS has not catered well to Britain’s ‘diverse’ population,” he added. Dr Chand referred to a previous Department of Health patient survey which revealed a consistent pattern of higher levels of dissatisfaction with NHS services among some minority ethnic groups, when compared with the white majority.
“Those responding to the survey from BAME backgrounds reported significantly poorer experiences (as hospital inpatients) than white British or Irish respondents, particularly on questions of prompt access, as well as their experience of involvement and choice,” the Manchester-based GP said. He also noted BAME leadership at high levels is “very poor” – there are very few ethnic minorities involved in the delivery of the service that they use.
Dr Farzana Hussain, an NHS clinical director and GP, was also critical about the lack of senior ethnic minorities in the healthcare system, recommending an investigation into the cause of this. “More needs to be done to look into why people aren’t coming forward (for these roles),” she said. “Is it that they don’t feel confident or empowered enough?”
Dr Hussain’s GP surgery is based in Newham, east London. The borough has one of the highest BAME populations in the country, with an estimated 73 per cent of the population hailing from an ethnic background. She said there was a significant lack of investment in the area, with evidence showing Newham was the second poorest borough in England. The first is Tower Hamlets in east London, which also has a substantial BAME population.
She said there was a link between the findings and the lack of funding is areas such as Newham.
Dr Farzana Hussain works as a GP in Newham, east London, which has a substantial BAME population
Both Dr Nagpaul and Dr Chand called for action, rather than more reviews and reports on inequalities. “We have known these problems have existed for decades, so further evidence-seeking exercises on ethnic disparities and inequalities while useful, should not deter the urgent action that is clearly needed,” Dr Nagpaul said. “The BMA believes that attention should now be on implementation of solutions to address the known ethnic disparities and inequalities, with any further research focused on where it is required to support or monitor action.”
Dr Chand added: “We have plenty of reports – we need action. Empty rhetoric makes no difference. A culture change in the long run and mandatory targets and penalties in the short term are essential.”
Ruth Watkinson, the lead author of the report, from the University of Manchester, said, “We need decisive policy action to improve equity of socio-economic opportunity and transformation of health and local services to ensure they meet the needs of the multi-ethnic English population.”
Co-author Alex Turner added the data showed the need for “more nuanced research” to understand the specific barriers to good health in older ethnic groups. “For example, Bangladeshi, Pakistani and Chinese ethnicities are often all categorised as ‘Asian’,” he said. “In our study, people of Bangladeshi and Pakistani ethnicity had the worst disadvantage in health, compared with white British, whereas people of Chinese ethnicity had a relative advantage.”
The analysis surveyed almost 1.4 million adults aged over 55, including more than 150,000 people who self-identified as belonging to an ethnic minority group
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.